Cargando…
A Genetic and Pharmacological Analysis of Isoprenoid Pathway by LC-MS/MS in Fission Yeast
Currently, statins are the only drugs acting on the mammalian isoprenoid pathway. The mammalian genes in this pathway are not easily amenable to genetic manipulation. Thus, it is difficult to study the effects of the inhibition of various enzymes on the intermediate and final products in the isopren...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492200/ https://www.ncbi.nlm.nih.gov/pubmed/23145048 http://dx.doi.org/10.1371/journal.pone.0049004 |
_version_ | 1782249080401952768 |
---|---|
author | Takami, Tomonori Fang, Yue Zhou, Xin Jaiseng, Wurentuya Ma, Yan Kuno, Takayoshi |
author_facet | Takami, Tomonori Fang, Yue Zhou, Xin Jaiseng, Wurentuya Ma, Yan Kuno, Takayoshi |
author_sort | Takami, Tomonori |
collection | PubMed |
description | Currently, statins are the only drugs acting on the mammalian isoprenoid pathway. The mammalian genes in this pathway are not easily amenable to genetic manipulation. Thus, it is difficult to study the effects of the inhibition of various enzymes on the intermediate and final products in the isoprenoid pathway. In fission yeast, antifungal compounds such as azoles and terbinafine are available as inhibitors of the pathway in addition to statins, and various isoprenoid pathway mutants are also available. Here in these mutants, treated with statins or antifungals, we quantified the final and intermediate products of the fission yeast isoprenoid pathway using liquid chromatography-mass spectrometry/mass spectrometry. In hmg1-1, a mutant of the gene encoding 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), ergosterol (a final sterol product), and squalene (an intermediate pathway product), were decreased to approximately 80% and 10%, respectively, compared with that of wild-type cells. Consistently in wild-type cells, pravastatin, an HMGR inhibitor decreased ergosterol and squalene, and the effect was more pronounced on squalene. In hmg1-1 mutant and in wild-type cells treated with pravastatin, the decrease in the levels of farnesyl pyrophosphate and geranylgeranyl pyrophosphate respectively was larger than that of ergosterol but was smaller than that of squalene. In Δerg6 or Δsts1 cells, mutants of the genes involved in the last step of the pathway, ergosterol was not detected, and the changes of intermediate product levels were distinct from that of hmg1-1 mutant. Notably, in wild-type cells miconazole and terbinafine only slightly decreased ergosterol level. Altogether, these studies suggest that the pleiotropic phenotypes caused by the hmg1-1 mutation and pravastatin might be due to decreased levels of isoprenoid pyrophosphates or other isoprenoid pathway intermediate products rather than due to a decreased ergosterol level. |
format | Online Article Text |
id | pubmed-3492200 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-34922002012-11-09 A Genetic and Pharmacological Analysis of Isoprenoid Pathway by LC-MS/MS in Fission Yeast Takami, Tomonori Fang, Yue Zhou, Xin Jaiseng, Wurentuya Ma, Yan Kuno, Takayoshi PLoS One Research Article Currently, statins are the only drugs acting on the mammalian isoprenoid pathway. The mammalian genes in this pathway are not easily amenable to genetic manipulation. Thus, it is difficult to study the effects of the inhibition of various enzymes on the intermediate and final products in the isoprenoid pathway. In fission yeast, antifungal compounds such as azoles and terbinafine are available as inhibitors of the pathway in addition to statins, and various isoprenoid pathway mutants are also available. Here in these mutants, treated with statins or antifungals, we quantified the final and intermediate products of the fission yeast isoprenoid pathway using liquid chromatography-mass spectrometry/mass spectrometry. In hmg1-1, a mutant of the gene encoding 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), ergosterol (a final sterol product), and squalene (an intermediate pathway product), were decreased to approximately 80% and 10%, respectively, compared with that of wild-type cells. Consistently in wild-type cells, pravastatin, an HMGR inhibitor decreased ergosterol and squalene, and the effect was more pronounced on squalene. In hmg1-1 mutant and in wild-type cells treated with pravastatin, the decrease in the levels of farnesyl pyrophosphate and geranylgeranyl pyrophosphate respectively was larger than that of ergosterol but was smaller than that of squalene. In Δerg6 or Δsts1 cells, mutants of the genes involved in the last step of the pathway, ergosterol was not detected, and the changes of intermediate product levels were distinct from that of hmg1-1 mutant. Notably, in wild-type cells miconazole and terbinafine only slightly decreased ergosterol level. Altogether, these studies suggest that the pleiotropic phenotypes caused by the hmg1-1 mutation and pravastatin might be due to decreased levels of isoprenoid pyrophosphates or other isoprenoid pathway intermediate products rather than due to a decreased ergosterol level. Public Library of Science 2012-11-07 /pmc/articles/PMC3492200/ /pubmed/23145048 http://dx.doi.org/10.1371/journal.pone.0049004 Text en © 2012 Takami et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Takami, Tomonori Fang, Yue Zhou, Xin Jaiseng, Wurentuya Ma, Yan Kuno, Takayoshi A Genetic and Pharmacological Analysis of Isoprenoid Pathway by LC-MS/MS in Fission Yeast |
title | A Genetic and Pharmacological Analysis of Isoprenoid Pathway by LC-MS/MS in Fission Yeast |
title_full | A Genetic and Pharmacological Analysis of Isoprenoid Pathway by LC-MS/MS in Fission Yeast |
title_fullStr | A Genetic and Pharmacological Analysis of Isoprenoid Pathway by LC-MS/MS in Fission Yeast |
title_full_unstemmed | A Genetic and Pharmacological Analysis of Isoprenoid Pathway by LC-MS/MS in Fission Yeast |
title_short | A Genetic and Pharmacological Analysis of Isoprenoid Pathway by LC-MS/MS in Fission Yeast |
title_sort | genetic and pharmacological analysis of isoprenoid pathway by lc-ms/ms in fission yeast |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492200/ https://www.ncbi.nlm.nih.gov/pubmed/23145048 http://dx.doi.org/10.1371/journal.pone.0049004 |
work_keys_str_mv | AT takamitomonori ageneticandpharmacologicalanalysisofisoprenoidpathwaybylcmsmsinfissionyeast AT fangyue ageneticandpharmacologicalanalysisofisoprenoidpathwaybylcmsmsinfissionyeast AT zhouxin ageneticandpharmacologicalanalysisofisoprenoidpathwaybylcmsmsinfissionyeast AT jaisengwurentuya ageneticandpharmacologicalanalysisofisoprenoidpathwaybylcmsmsinfissionyeast AT mayan ageneticandpharmacologicalanalysisofisoprenoidpathwaybylcmsmsinfissionyeast AT kunotakayoshi ageneticandpharmacologicalanalysisofisoprenoidpathwaybylcmsmsinfissionyeast AT takamitomonori geneticandpharmacologicalanalysisofisoprenoidpathwaybylcmsmsinfissionyeast AT fangyue geneticandpharmacologicalanalysisofisoprenoidpathwaybylcmsmsinfissionyeast AT zhouxin geneticandpharmacologicalanalysisofisoprenoidpathwaybylcmsmsinfissionyeast AT jaisengwurentuya geneticandpharmacologicalanalysisofisoprenoidpathwaybylcmsmsinfissionyeast AT mayan geneticandpharmacologicalanalysisofisoprenoidpathwaybylcmsmsinfissionyeast AT kunotakayoshi geneticandpharmacologicalanalysisofisoprenoidpathwaybylcmsmsinfissionyeast |